info@marketresearchfuture.com   📞  +1 (855) 661-4441(US)   📞  +44 1720 412 167(UK)
Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players’ financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

POC Blood Gas and Electrolyte Companies

Here are brief descriptions of some companies that are known for their involvement in the development and manufacturing of Point-of-Care (POC) Blood Gas and Electrolyte testing devices.

POC Blood Gas and Electrolyte Key CompaniesLatest POC Blood Gas and Electrolyte Companies Update



  • Nov 2023: Listed in Frankfurt Advisors are assisting Siemens Healthineers in researching possibilities for the division. According to them, the evaluation might result in the sale or carve-out of its in-vitro diagnostics division, which tests blood and tissue samples to detect illnesses and disorders. The stock reached its highest level in three months on Friday morning, rising as much as 4.7%. The source stated that although all alternatives are still open, the review might result in the unit being sold. They said discussions are still in their early stages and that no banks have been given mandates. The company's diagnostics business had a 20% decline in revenue in the third quarter due to a decline in test demand. Restructuring is also underway in the diagnostics industry.




  • May 2023: A long-acting, broad-spectrum cephalosporin antibiotic is called Roche's Rocephin. F. Hoffmann-La Roche Ltd. is credited. Roche, a Swiss healthcare company, has sold its mainland China sales rights to Hasten Biopharmaceutical. With the purchase completed earlier in 2023, there will now be an adjustment period between the two corporations. Hasten also acquired Rocephin's intellectual property, trademarks, and marketing authority. Parenterally administered, rocephin is a long-acting, broad-spectrum cephalosporin antibiotic. It is approved for treating sepsis, meningitis, and infections of the stomach, bones, joints, soft tissues, and skin in adults and children.


List of POC Blood Gas and Electrolyte Key companies in the market

  • Siemens

  • Abbott

  • Hoffman-La Roche Ltd.

  • Radiometer

  • Nova medical

  • Edan Instruments Inc.

  • Instrumentation Laboratory

Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Kindly complete the form below to receive a free sample of this Report
Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.